卡利迪生物治疗公司完成了4.25M美元的股票供应,但其股票价格下跌超过30%。 Calidi Biotherapeutics completes $4.25M stock offering, but its stock price drops over 30%.

卡利迪生物治疗公司是一家临床阶段生物技术公司,已最后敲定了价值425万美元的公共股票供应,发行500万股,每股0.85美元。 Calidi Biotherapeutics, a clinical-stage biotech firm, has finalized a $4.25 million public stock offering, issuing 5 million shares at $0.85 each. 这些资金将用于公司的一般用途和周转资金。 The funds will be used for general corporate purposes and working capital. 尽管如此,公司股票在公告上下跌了30%以上。 Despite the offering, the company's stock fell by over 30% on the announcement. Ladenburg Thalmann & Co. Inc.作为交易的独家安置代理商。 Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the transaction.